{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T06:41:41Z","timestamp":1794638501836,"version":"4.9.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T00:00:00Z","timestamp":1741564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"DOI":"10.1186\/s12943-025-02274-1","type":"journal-article","created":{"date-parts":[[2025,3,9]],"date-time":"2025-03-09T23:08:08Z","timestamp":1741561688000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Modulating lipid metabolism by nanoparticles (NPs)-mediated ACSL3 silencing to inhibit hepatocellular carcinoma growth and metastasis"],"prefix":"10.1186","volume":"24","author":[{"given":"Linzhuo","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunhao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wende","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senlin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phei Er","family":"Saw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoding","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,10]]},"reference":[{"key":"2274_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer Clin J. 2023;73:17\u201348.","journal-title":"CA Cancer Clin J"},{"key":"2274_CR2","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1016\/j.jhep.2022.08.021","volume":"77","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, Laversanne M, McGlynn KA, Soerjomataram I. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598\u2013606.","journal-title":"J Hepatol"},{"key":"2274_CR3","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3748\/wjg.v13.i3.414","volume":"13","author":"K Uka","year":"2007","unstructured":"Uka K, Aikata H, Takaki S, Shirakawa H, Jeong SC, Yamashina K, Hiramatsu A, Kodama H, Takahashi S, Chayama K. Clinical features and prognosis of patients with extrahepatic metastases from hepatocellular carcinoma. World J Gastroenterol. 2007;13:414\u201320.","journal-title":"World J Gastroenterol"},{"key":"2274_CR4","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3892\/mco.2014.259","volume":"2","author":"H Aino","year":"2014","unstructured":"Aino H, Sumie S, Niizeki T, Kuromatsu R, Tajiri N, Nakano M, Satani M, Yamada S, Okamura S, Shimose S, et al. Clinical characteristics and prognostic factors for advanced hepatocellular carcinoma with extrahepatic metastasis. Mol Clin Oncol. 2014;2:393\u20138.","journal-title":"Mol Clin Oncol"},{"key":"2274_CR5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1111\/j.1440-1746.2011.06917.x","volume":"27","author":"SM Jung","year":"2012","unstructured":"Jung SM, Jang JW, You CR, Yoo SH, Kwon JH, Bae SH, Choi JY, Yoon SK, Chung KW, Kay CS, Jung HS. Role of intrahepatic tumor control in the prognosis of patients with hepatocellular carcinoma and extrahepatic metastases. J Gastroenterol Hepatol. 2012;27:684\u20139.","journal-title":"J Gastroenterol Hepatol"},{"key":"2274_CR6","doi-asserted-by":"publisher","first-page":"1307","DOI":"10.1016\/j.cmet.2021.04.002","volume":"33","author":"MR Zanotelli","year":"2021","unstructured":"Zanotelli MR, Zhang J, Reinhart-King CA. Mechanoresponsive metabolism in cancer cell migration and metastasis. Cell Metab. 2021;33:1307\u201321.","journal-title":"Cell Metab"},{"key":"2274_CR7","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s41568-021-00388-4","volume":"21","author":"AJ Hoy","year":"2021","unstructured":"Hoy AJ, Nagarajan SR, Butler LM. Tumour fatty acid metabolism in the context of therapy resistance and obesity. Nat Rev Cancer. 2021;21:753\u201366.","journal-title":"Nat Rev Cancer"},{"key":"2274_CR8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cmet.2019.11.010","volume":"31","author":"MT Snaebjornsson","year":"2020","unstructured":"Snaebjornsson MT, Janaki-Raman S, Schulze A. Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer. Cell Metab. 2020;31:62\u201376.","journal-title":"Cell Metab"},{"key":"2274_CR9","doi-asserted-by":"publisher","first-page":"e20201606","DOI":"10.1084\/jem.20201606","volume":"218","author":"X Bian","year":"2020","unstructured":"Bian X, Liu R, Meng Y, Xing D, Xu D, Lu Z. Lipid metabolism and cancer. J Exp Med. 2020;218:e20201606.","journal-title":"J Exp Med"},{"key":"2274_CR10","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41568-020-00320-2","volume":"21","author":"G Bergers","year":"2021","unstructured":"Bergers G, Fendt SM. The metabolism of cancer cells during metastasis. Nat Rev Cancer. 2021;21:162\u201380.","journal-title":"Nat Rev Cancer"},{"key":"2274_CR11","doi-asserted-by":"publisher","first-page":"e1600200","DOI":"10.1126\/sciadv.1600200","volume":"2","author":"RJ DeBerardinis","year":"2016","unstructured":"DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv. 2016;2:e1600200.","journal-title":"Sci Adv"},{"key":"2274_CR12","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/s41568-021-00378-6","volume":"21","author":"I Mart\u00ednez-Reyes","year":"2021","unstructured":"Mart\u00ednez-Reyes I, Chandel NS. Cancer metabolism: looking forward. Nat Rev Cancer. 2021;21:669\u201380.","journal-title":"Nat Rev Cancer"},{"key":"2274_CR13","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","volume":"34","author":"NN Pavlova","year":"2022","unstructured":"Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022;34:355\u201377.","journal-title":"Cell Metab"},{"key":"2274_CR14","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1016\/j.jhep.2011.08.025","volume":"56","author":"LP Bechmann","year":"2012","unstructured":"Bechmann LP, Hannivoort RA, Gerken G, Hotamisligil GS, Trauner M, Canbay A. The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2012;56:952\u201364.","journal-title":"J Hepatol"},{"key":"2274_CR15","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/s41575-019-0217-8","volume":"16","author":"L Satriano","year":"2019","unstructured":"Satriano L, Lewinska M, Rodrigues PM, Banales JM, Andersen JB. Metabolic rearrangements in primary liver cancers: cause and consequences. Nat Rev Gastroenterol Hepatol. 2019;16:748\u201366.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"2274_CR16","doi-asserted-by":"publisher","first-page":"100479","DOI":"10.1016\/j.jhepr.2022.100479","volume":"4","author":"B Paul","year":"2022","unstructured":"Paul B, Lewinska M, Andersen JB. Lipid alterations in chronic liver disease and liver cancer. JHEP Rep. 2022;4:100479.","journal-title":"JHEP Rep"},{"key":"2274_CR17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nrm2335","volume":"9","author":"MP Wymann","year":"2008","unstructured":"Wymann MP, Schneiter R. Lipid signalling in disease. Nat Rev Mol Cell Biol. 2008;9:162\u201376.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2274_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/nrm2330","volume":"9","author":"G van Meer","year":"2008","unstructured":"van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. Nat Rev Mol Cell Biol. 2008;9:112\u201324.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2274_CR19","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1038\/s43018-023-00702-z","volume":"5","author":"FCE Vogel","year":"2024","unstructured":"Vogel FCE, Chaves-Filho AB, Schulze A. Lipids as mediators of cancer progression and metastasis. Nat Cancer. 2024;5:16\u201329.","journal-title":"Nat Cancer"},{"key":"2274_CR20","doi-asserted-by":"publisher","first-page":"3679","DOI":"10.1158\/0008-5472.CAN-20-3944","volume":"81","author":"APY Ma","year":"2021","unstructured":"Ma APY, Yeung CLS, Tey SK, Mao X, Wong SWK, Ng TH, Ko FCF, Kwong EML, Tang AHN, Ng IO, et al. Suppression of ACADM-mediated fatty acid oxidation promotes hepatocellular carcinoma via aberrant CAV1\/SREBP1 signaling. Cancer Res. 2021;81:3679\u201392.","journal-title":"Cancer Res"},{"key":"2274_CR21","doi-asserted-by":"publisher","first-page":"5181","DOI":"10.1038\/s41467-023-40943-1","volume":"14","author":"S Hendrix","year":"2023","unstructured":"Hendrix S, Kingma J, Ottenhoff R, Valiloo M, Svecla M, Zijlstra LF, Sachdev V, Kovac K, Levels JHM, Jongejan A, et al. Hepatic SREBP signaling requires SPRING to govern systemic lipid metabolism in mice and humans. Nat Commun. 2023;14:5181.","journal-title":"Nat Commun"},{"key":"2274_CR22","doi-asserted-by":"publisher","first-page":"e141529","DOI":"10.1172\/JCI141529","volume":"131","author":"H Ito","year":"2021","unstructured":"Ito H, Nakamae I, Kato J-y, Yoneda-Kato N. Stabilization of fatty acid synthesis enzyme acetyl-CoA carboxylase 1 suppresses acute myeloid leukemia development. J Clin Invest. 2021;131:e141529.","journal-title":"J Clin Invest"},{"key":"2274_CR23","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.cmet.2018.08.020","volume":"29","author":"JSV Lally","year":"2019","unstructured":"Lally JSV, Ghoshal S, DePeralta DK, Moaven O, Wei L, Masia R, Erstad DJ, Fujiwara N, Leong V, Houde VP, et al. Inhibition of acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma. Cell Metab. 2019;29:174\u201382.","journal-title":"Cell Metab"},{"key":"2274_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41568-022-00543-5","volume":"23","author":"DA Guertin","year":"2023","unstructured":"Guertin DA, Wellen KE. Acetyl-CoA metabolism in cancer. Nat Rev Cancer. 2023;23:156\u201372.","journal-title":"Nat Rev Cancer"},{"key":"2274_CR25","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7:6.","journal-title":"Nat Rev Dis Primers"},{"key":"2274_CR26","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1002\/hep.22506","volume":"48","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology. 2008;48:1312\u201327.","journal-title":"Hepatology"},{"key":"2274_CR27","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.cell.2013.09.006","volume":"155","author":"DC Koboldt","year":"2013","unstructured":"Koboldt DC, Steinberg KM, Larson DE, Wilson RK, Mardis ER. The next-generation sequencing revolution and its impact on genomics. Cell. 2013;155:27\u201338.","journal-title":"Cell"},{"key":"2274_CR28","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/nrg2841","volume":"11","author":"M Meyerson","year":"2010","unstructured":"Meyerson M, Gabriel S, Getz G. Advances in Understanding cancer genomes through second-generation sequencing. Nat Rev Genet. 2010;11:685\u201396.","journal-title":"Nat Rev Genet"},{"key":"2274_CR29","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/j.molcel.2015.05.004","volume":"58","author":"A Reuter Jason","year":"2015","unstructured":"Reuter Jason A, Spacek DV, Snyder Michael P. High-throughput sequencing technologies. Mol Cell. 2015;58:586\u201397.","journal-title":"Mol Cell"},{"key":"2274_CR30","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nature20791","volume":"541","author":"G Pascual","year":"2017","unstructured":"Pascual G, Avgustinova A, Mejetta S, Martin M, Castellanos A, Attolini CS, Berenguer A, Prats N, Toll A, Hueto JA, et al. Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature. 2017;541:41\u20135.","journal-title":"Nature"},{"key":"2274_CR31","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.cell.2009.05.036","volume":"138","author":"MV Chakravarthy","year":"2009","unstructured":"Chakravarthy MV, Lodhi IJ, Yin L, Malapaka RRV, Xu HE, Turk J, Semenkovich CF. Identification of a physiologically relevant endogenous ligand for PPAR\u03b1 in liver. Cell. 2009;138:476\u201388.","journal-title":"Cell"},{"key":"2274_CR32","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/cr.2010.13","volume":"20","author":"Y-X Wang","year":"2010","unstructured":"Wang Y-X. PPARs: diverse regulators in energy metabolism and metabolic diseases. Cell Res. 2010;20:124\u201337.","journal-title":"Cell Res"},{"key":"2274_CR33","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrc3214","volume":"12","author":"JM Peters","year":"2012","unstructured":"Peters JM, Shah YM, Gonzalez FJ. The role of peroxisome proliferator-activated receptors in carcinogenesis and chemoprevention. Nat Rev Cancer. 2012;12:181\u201395.","journal-title":"Nat Rev Cancer"},{"key":"2274_CR34","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-021-01036-y","volume":"14","author":"X Su","year":"2021","unstructured":"Su X, Zhao L, Shi Y, Zhang R, Long Q, Bai S, Luo Q, Lin Y, Zou X, Ghazanfar S, et al. Clonal evolution in liver cancer at single-cell and single-variant resolution. J Hematol Oncol. 2021;14:22.","journal-title":"J Hematol Oncol"},{"key":"2274_CR35","doi-asserted-by":"publisher","first-page":"D1425","DOI":"10.1093\/nar\/gkac959","volume":"51","author":"Y Han","year":"2022","unstructured":"Han Y, Wang Y, Dong X, Sun D, Liu Z, Yue J, Wang H, Li T, Wang C. TISCH2: expanded datasets and new tools for single-cell transcriptome analyses of the tumor microenvironment. Nucleic Acids Res. 2022;51:D1425\u201331.","journal-title":"Nucleic Acids Res"},{"key":"2274_CR36","doi-asserted-by":"crossref","unstructured":"Rakhshandehroo M, Knoch B, M\u00fcller M, Kersten S. Peroxisome proliferator-activated receptor alpha target genes. PPAR Res. 2010, 2010:612089.","DOI":"10.1155\/2010\/612089"},{"key":"2274_CR37","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1210\/er.2018-00064","volume":"39","author":"N Bougarne","year":"2018","unstructured":"Bougarne N, Weyers B, Desmet SJ, Deckers J, Ray DW, Staels B, De Bosscher K. Molecular actions of PPAR\u03b1 in lipid metabolism and inflammation. Endocr Rev. 2018;39:760\u2013802.","journal-title":"Endocr Rev"},{"key":"2274_CR38","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.cmet.2013.05.017","volume":"18","author":"E Currie","year":"2013","unstructured":"Currie E, Schulze A, Zechner R, Walther Tobias C. Farese Robert V: cellular fatty acid metabolism and cancer. Cell Metab. 2013;18:153\u201361.","journal-title":"Cell Metab"},{"key":"2274_CR39","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.7150\/ijbs.69802","volume":"18","author":"J Quan","year":"2022","unstructured":"Quan J, Cheng C, Tan Y, Jiang N, Liao C, Liao W, Cao Y, Luo X. Acyl-CoA synthetase long-chain 3-mediated fatty acid oxidation is required for TGFbeta1-induced epithelial-mesenchymal transition and metastasis of colorectal carcinoma. Int J Biol Sci. 2022;18:2484\u201396.","journal-title":"Int J Biol Sci"},{"key":"2274_CR40","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1194\/jlr.M700050-JLR200","volume":"48","author":"Y Fujimoto","year":"2007","unstructured":"Fujimoto Y, Itabe H, Kinoshita T, Homma KJ, Onoduka J, Mori M, Yamaguchi S, Makita M, Higashi Y, Yamashita A, Takano T. Involvement of ACSL in local synthesis of neutral lipids in cytoplasmic lipid droplets in human hepatocyte HuH7. J Lipid Res. 2007;48:1280\u201392.","journal-title":"J Lipid Res"},{"key":"2274_CR41","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, Rossi JJ, Han S-p. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18:421\u201346.","journal-title":"Nat Rev Drug Discov"},{"key":"2274_CR42","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/418244a","volume":"418","author":"GJ Hannon","year":"2002","unstructured":"Hannon GJ. RNA interference. Nature. 2002;418:244\u201351.","journal-title":"Nature"},{"key":"2274_CR43","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nrd2742","volume":"8","author":"KA Whitehead","year":"2009","unstructured":"Whitehead KA, Langer R, Anderson DG. Knocking down barriers: advances in SiRNA delivery. Nat Rev Drug Discov. 2009;8:129\u201338.","journal-title":"Nat Rev Drug Discov"},{"key":"2274_CR44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.addr.2019.05.004","volume":"144","author":"Y Dong","year":"2019","unstructured":"Dong Y, Siegwart DJ, Anderson DG. Strategies, design, and chemistry in SiRNA delivery systems. Adv Drug Deliv Rev. 2019;144:133\u201347.","journal-title":"Adv Drug Deliv Rev"},{"key":"2274_CR45","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.addr.2017.07.021","volume":"115","author":"Z Zhou","year":"2017","unstructured":"Zhou Z, Liu X, Zhu D, Wang Y, Zhang Z, Zhou X, Qiu N, Chen X, Shen Y. Nonviral cancer gene therapy: delivery cascade and vector nanoproperty integration. Adv Drug Deliv Rev. 2017;115:115\u201354.","journal-title":"Adv Drug Deliv Rev"},{"key":"2274_CR46","doi-asserted-by":"publisher","first-page":"2305923","DOI":"10.1002\/smll.202305923","volume":"20","author":"R Xu","year":"2024","unstructured":"Xu R, Huang L, Liu J, Zhang Y, Xu Y, Li R, Su S, Xu X. Remodeling of mitochondrial metabolism by a mitochondria-targeted RNAi nanoplatform for effective cancer therapy. Small. 2024;20:2305923.","journal-title":"Small"},{"key":"2274_CR47","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1016\/j.apsb.2022.12.004","volume":"13","author":"K Yang","year":"2023","unstructured":"Yang K, Xu L, Xu Y, Shen Q, Qin T, Yu Y, Nie Y, Yao H, Xu X. Nanoparticles (NPs)-mediated LncBCMA Silencing to promote eEF1A1 ubiquitination and suppress breast cancer growth and metastasis. Acta Pharma Sin B. 2023;13:3489\u2013502.","journal-title":"Acta Pharma Sin B"},{"key":"2274_CR48","doi-asserted-by":"publisher","first-page":"20220013","DOI":"10.1002\/EXP.20220013","volume":"2","author":"Z Huang","year":"2022","unstructured":"Huang Z, Liu S, Lu N, Xu L, Shen Q, Huang Z, Huang Z, Saw PE, Xu X. Nucleus-specific RNAi nanoplatform for targeted regulation of nuclear LncRNA function and effective cancer therapy. Exploration. 2022;2:20220013.","journal-title":"Exploration"},{"key":"2274_CR49","doi-asserted-by":"publisher","first-page":"2207118","DOI":"10.1002\/advs.202207118","volume":"10","author":"S Li","year":"2023","unstructured":"Li S, Xu L, Wu G, Huang Z, Huang L, Zhang F, Wei C, Shen Q, Li R, Zhang L, Xu X. Remodeling Serine synthesis and metabolism via nanoparticles (NPs)-mediated CFL1 Silencing to enhance the sensitivity of hepatocellular carcinoma to Sorafenib. Adv Sci. 2023;10:2207118.","journal-title":"Adv Sci"},{"key":"2274_CR50","doi-asserted-by":"publisher","first-page":"1802565","DOI":"10.1002\/smll.201802565","volume":"14","author":"X Xu","year":"2018","unstructured":"Xu X, Wu J, Liu S, Saw PE, Tao W, Li Y, Krygsman L, Yegnasubramanian S, De Marzo AM, Shi J, et al. Redox-responsive nanoparticle-mediated systemic RNAi for effective cancer therapy. Small. 2018;14:1802565.","journal-title":"Small"},{"key":"2274_CR51","doi-asserted-by":"publisher","first-page":"5967","DOI":"10.1021\/acs.nanolett.9b01660","volume":"19","author":"PE Saw","year":"2019","unstructured":"Saw PE, Yao H, Lin C, Tao W, Farokhzad OC, Xu X. Stimuli-responsive polymer-prodrug hybrid nanoplatform for multistage SiRNA delivery and combination cancer therapy. Nano Lett. 2019;19:5967\u201374.","journal-title":"Nano Lett"},{"key":"2274_CR52","doi-asserted-by":"publisher","first-page":"2618","DOI":"10.1021\/acsnano.6b07195","volume":"11","author":"X Xu","year":"2017","unstructured":"Xu X, Wu J, Liu Y, Saw PE, Tao W, Yu M, Zope H, Si M, Victorious A, Rasmussen J, et al. Multifunctional envelope-type SiRNA delivery nanoparticle platform for prostate cancer therapy. ACS Nano. 2017;11:2618\u201327.","journal-title":"ACS Nano"},{"key":"2274_CR53","doi-asserted-by":"publisher","first-page":"6288","DOI":"10.1002\/anie.200902672","volume":"49","author":"K Knop","year":"2010","unstructured":"Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed. 2010;49:6288\u2013308.","journal-title":"Angew Chem Int Ed"},{"key":"2274_CR54","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/nm1469","volume":"12","author":"PS Steeg","year":"2006","unstructured":"Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med. 2006;12:895\u2013904.","journal-title":"Nat Med"},{"key":"2274_CR55","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.cell.2011.09.024","volume":"147","author":"S Valastyan","year":"2011","unstructured":"Valastyan S, Weinberg Robert A. Tumor metastasis: molecular insights and evolving paradigms. Cell. 2011;147:275\u201392.","journal-title":"Cell"},{"key":"2274_CR56","doi-asserted-by":"crossref","unstructured":"Lambert AW, Pattabiraman DR, Weinberg RA. Emerging biological principles of metastasis. Cell. 2017;168:670\u201391.","DOI":"10.1016\/j.cell.2016.11.037"},{"key":"2274_CR57","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41586-020-2623-z","volume":"585","author":"JM Ubellacker","year":"2020","unstructured":"Ubellacker JM, Tasdogan A, Ramesh V, Shen B, Mitchell EC, Martin-Sandoval MS, Gu Z, McCormick ML, Durham AB, Spitz DR, et al. Lymph protects metastasizing melanoma cells from ferroptosis. Nature. 2020;585:113\u20138.","journal-title":"Nature"},{"key":"2274_CR58","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13045-022-01297-1","volume":"15","author":"Y Xie","year":"2022","unstructured":"Xie Y, Wang B, Zhao Y, Tao Z, Wang Y, Chen G, Hu X. Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis. J Hematol Oncol. 2022;15:72.","journal-title":"J Hematol Oncol"},{"key":"2274_CR59","doi-asserted-by":"publisher","first-page":"eabb9200","DOI":"10.1126\/sciadv.abb9200","volume":"6","author":"M Rossi Sebastiano","year":"2020","unstructured":"Rossi Sebastiano M, Pozzato C, Saliakoura M, Yang Z, Peng RW, Galie M, Oberson K, Simon HU, Karamitopoulou E, Konstantinidou G. ACSL3-PAI-1 signaling axis mediates tumor-stroma cross-talk promoting pancreatic cancer progression. Sci Adv. 2020;6:eabb9200.","journal-title":"Sci Adv"},{"key":"2274_CR60","doi-asserted-by":"publisher","first-page":"20153624","DOI":"10.3390\/ijms20153624","volume":"20","author":"M Rossi Sebastiano","year":"2019","unstructured":"Rossi Sebastiano M, Konstantinidou G. Targeting long chain acyl-CoA synthetases for cancer therapy. Int J Mol Sci. 2019;20:20153624.","journal-title":"Int J Mol Sci"},{"key":"2274_CR61","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","volume":"16","author":"JA Kulkarni","year":"2021","unstructured":"Kulkarni JA, Witzigmann D, Thomson SB, Chen S, Leavitt BR, Cullis PR, van der Meel R. The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 2021;16:630\u201343.","journal-title":"Nat Nanotechnol"},{"key":"2274_CR62","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","volume":"23","author":"K Paunovska","year":"2022","unstructured":"Paunovska K, Loughrey D, Dahlman JE. Drug delivery systems for RNA therapeutics. Nat Rev Genet. 2022;23:265\u201380.","journal-title":"Nat Rev Genet"},{"key":"2274_CR63","doi-asserted-by":"publisher","first-page":"6975","DOI":"10.1021\/acs.jmedchem.2c00024","volume":"65","author":"JM Sasso","year":"2022","unstructured":"Sasso JM, Ambrose BJB, Tenchov R, Datta RS, Basel MT, DeLong RK, Zhou QA. The progress and promise of RNA medicine-an arsenal of targeted treatments. J Med Chem. 2022;65:6975\u20137015.","journal-title":"J Med Chem"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02274-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-025-02274-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-025-02274-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T10:55:08Z","timestamp":1741604108000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-025-02274-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,10]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2274"],"URL":"https:\/\/doi.org\/10.1186\/s12943-025-02274-1","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,10]]},"assertion":[{"value":"11 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All HCC tumor samples were collected with the informed consent of the patients in accordance with the International Ethical Guidelines for Biomedical Research Involving Human Subjects (CIOMS). The study was approved by the Institutional Review Board (IRB) of Sun Yat-Sen Memorial Hospital. All animal experiments were performed by a protocol approved by the Institutional Animal Care and Use Committee at Sun Yat-Sen Memorial Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"73"}}